ClinicalTrials.gg
TerminatedNCT05721222Updated Nov 19, 2026Results posted

Trial of PRO1160 (GEN1160) in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) (PRO1160-001)

A Phase 1/2 interventional study of GEN1160 in Renal Cell Carcinoma, Nasopharyngeal Carcinoma and Non Hodgkin Lymphoma, sponsored by Genmab. Terminated at 17 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Genmab · Phase 1/2, Interventional, and Treatment

How we know

Why this study was terminated
Genmab has decided to discontinue the clinical development of GEN1160 due to slow enrolment
Updated Nov 19, 2026Results postedStudy documents posted+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
42
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,144 studies in Carcinoma, Renal Cell with a site in United States — 154 open to participants now, 278 under way, 26 of them phase 3. Carcinoma, Renal Cell · United States.

Enrollment
474th of 1,010
42 · median 40
Started
2023
with 51 others
Phase 1/2
147 of 1,144
30 open now
Registered
986th of 1,144
by date

Among the 1,144 studies in Carcinoma, Renal Cell with a site in United States, this one is the 474th largest by enrollment of the 1,010 interventional ones that give a count, is one of 52 that started in 2023, is one of 147 in phase 1/2, and was the 986th registered.

Carcinoma, Renal Cell

2,043 studies on the registry are indexed under Carcinoma, Renal Cell; 395 are open to participants now.

Browse Carcinoma, Renal Cell studies →

Open to participants now

154 of the 1,144 studies in Carcinoma, Renal Cell with a site in United States are open now. Recruiting first, the newest first:

149 more — sign in →

All 154 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 308 Carcinoma, Renal Cell studies recruiting now, 255 (83%) set no upper age limit and 18 (6%) stop at 75 or younger; 21 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,144 studies in Carcinoma, Renal Cell with a site in United States, or all of them as a file.
02

Study summary

Brief Summary:

This study will test the safety, including side effects, and determine the characteristics of a drug called GEN1160 (PRO1160) in participants with solid tumors and blood cancers.

Participants will have cancer that has spread through the body (metastatic) or cannot be removed with surgery (unresectable) or relapsed or refractory to prior treatments.

This Phase 1/2 study will have three parts. The dose escalation part of the study will find out how much and how frequently GEN1160 should be given to participants. The expansion Part A and expansion Part B will use the dose and schedule found in the dose escalation part to find out how safe GEN1160 is and if it works to treat the diseases under study. The diseases under study will be Renal Cell Carcinoma (RCC), Nasopharyngeal Carcinoma (NPC) and Non-Hodgkin Lymphoma (NHL) in Escalation and diffuse large B-cell lymphoma (DLBCL) in expansion Part A and Part B.

Read the detailed description

This is a Phase 1/2 study of GEN1160, a CD70 targeted antibody-drug conjugate, to evaluate the safety, tolerability, pharmacokinetics (PK), and antitumor activity of GEN1160 in participants with selected locally advanced /or metastatic solid and hematologic malignancies, including RCC, NPC and NHL. This study consists of 3 parts, Dose Escalation, Expansion Part A and Expansion Part B.

Dose escalation may evaluate up to 5 dose levels of GEN1160 on Day 1 of a 21 day cycle by intravenous (IV) infusion.

Expansion will be initiated at a dose level based on a comprehensive analysis of safety, tolerability, clinical PK, pharmacodynamics (PD) and activity data from the dose escalation. Expansion will be conducted in 1 cohort of up to 10 participants (expansion Part A) and 2 further cohorts (expansion Part B), each with up to 25 participants per cohort.

Participants will continue to receive study treatment until the first instance of disease progression, unacceptable toxicity, investigator decision, consent withdrawal, study termination by the Sponsor, initiation of non-GEN1160 anticancer therapy, participant noncompliance, pregnancy, or death.

03

Conditions studied

  • Renal Cell Carcinoma
  • Nasopharyngeal Carcinoma
  • Non Hodgkin Lymphoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Dose Escalation: Key Inclusion Criteria:

  • All participants must have confirmed diagnosis of one of the following tumor types:

    • RCC, including clear cell renal cell carcinoma (ccRCC) or papillary RCC
    • Metastatic or Epstein Barr virus (EBV)-associated NPC not amenable to further local therapies (EBV association may have been determined by testing on tumor tissue or peripheral blood)
    • Advanced (Stage III or IV) NHL, including diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) requiring systemic therapy, and mantle cell lymphoma (MCL)
  • Participants must have relapsed or refractory disease following prior systemic therapies known to confer clinical benefit. At minimum, participants should have received the following therapies (unless deemed ineligible, refused by the participant, or not available in the region):

    • Participants with RCC must have received a minimum of one prior treatment regimen, and have received a tyrosine kinase inhibitor (TKI) and a programmed cell death (ligand) ([PD[L)])-1 inhibitor
    • Participants with EBV-associated NPC must have received a minimum of one prior treatment regimen, which must include a platinum-based chemotherapy regimen
    • Participants with DLBCL must have received a minimum of 2 prior treatment regimens, including a multi-agent chemoimmunotherapy regimen given with curative intent (eg, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone [R-CHOP]), and participants must have received intensive salvage chemotherapy with hematopoietic stem cell transplant () if considered eligible by the investigator
    • Participants with FL must have received a minimum of 2 prior treatment regimens, which must include a multi-agent chemoimmunotherapy regimen including an anti-CD20 agent
    • Participants with mantle cell lymphoma (MCL) must have received a minimum of 2 prior treatment regimens, which must include a multi-agent chemoimmunotherapy regimen including an anti-CD20 agent
  • at baseline:

    • Participants with RCC and NPC must have measurable disease as defined per (RECIST), Version 1.1 (Eisenhauer et al., 2009)
    • Participants with NHL must have measurable disease as defined by the Lugano Classification (Cheson et al., 2014)
    • Participants must be willing to provide a pre-treatment tumor specimen (archival or new tissue samples). If a new tissue biopsy is required, procedures more invasive than a core biopsy or significant risk procedures for which the procedure-associated absolute risk of mortality or major morbidity in the participant's clinical setting and specific institution is 2% or higher, should not be utilized.

Dose Escalation Key Exclusion Criteria:

  • Prior treatment with anti-CD70 directed therapy
  • Prior therapy with an antibody-drug conjugate (ADC) with a topoisomerase 1 inhibitor payload
  • Prior allogeneic hematopoietic stem cell transplant (HSCT). Participants with prior autologous HSCT must have completed the procedure at least 100 days prior to the first dose of study drug.
  • Known active central nervous system metastases, including carcinomatous meningitis. Participants with may participate provided the metastases have been treated and are stable for at least 4 weeks prior to the first dose of study drug, they have no new or enlarging brain metastases and have discontinued prescribed for symptoms associated with brain metastases for at least 7 days prior to the first dose of study drug. Participants with a history of brain metastases, suspected new brain metastases, or a diagnosis of RCC should have a magnetic resonance imaging (MRI) of the brain at screening.

Expansion: Key Inclusion Criteria:

  • Has pathological diagnosis of DLBCL, not otherwise specified (NOS) as defined by the World Health Organization (WHO) 2016 classification including both de novo or histologically transformed.
  • Has relapsed or refractory disease with no available standard therapy or is not a candidate for available standard therapy, and for whom, in the opinion of the investigator, experimental therapy with GEN1160 may be beneficial. Participant must have received at least 2 systemic treatment regimens including CD20-containing chemoimmunotherapy.
  • Has measurable disease according to the 2014 Lugano criteria (Cheson et al., 2014):

    • A fluorodeoxyglucose (FDG)-positron emission tomography (PET) scan demonstrating positive lesion compatible with computed tomography (CT)- or MRI-defined anatomical tumor sites; AND
    • A CT scan (or MRI) with involvement of ≥ 1 measurable nodal lesion (long axis > 1.5 centimeters (cm) and short axis > 1.0 cm) and/or ≥ 1 measurable extranodal lesion (long axis > 1.0 cm).
  • Has (ECOG) performance status of 0, 1, or 2
  • Has a fresh biopsy (if clinically feasible and not considered as a high-risk procedure) or an archival tumor biopsy and submit to the central laboratory for CD70 assay
  • Has acceptable laboratory test results per protocol

Expansion: Key Exclusion Criteria:

  • Primary central nervous system (CNS) tumor or known CNS involvement.
  • Has been exposed to any of the following prior therapies within the specified timeframes:

    • Received prior CD70-targeting therapy, eg, CD70-directed chimeric antigen receptor T-cell (CAR-T) therapy, anti-CD70 monoclonal antibody (mAb), CD3 x CD70 bispecific monoclonal antibody (bsAb), or CD70 antibody-drug conjugate.
    • Autologous stem cell transplant within 60 days prior to the first dose of GEN1160.
    • Allogeneic stem cell transplant within 90 days prior to the first dose of GEN1160.
    • Chemotherapy within 2 weeks or major surgery within 4 weeks of the first dose of GEN1160.
    • Curative radiotherapy within 4 weeks or palliative radiotherapy within 2 weeks prior to the first dose of GEN1160.
    • Treatment with an investigational drug within 4 weeks or 5 half-lives of the drug, whichever is shorter, prior to the first dose of GEN1160 or currently receiving any other investigational agents.
    • Prior treatment with live, attenuated vaccines within 30 days prior to the first dose of GEN1160. Examples of include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus Calmette-Guérin, and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (eg, FluMist®) are live attenuated vaccines and are not allowed. Experimental and/or nonauthorized coronavirus disease (SARS-CoV-2) vaccinations are not allowed.
    • Receiving drugs or systemic corticosteroids such as prednisone at doses > 25 milligrams (mg) daily or its equivalent within 14 days prior to the first dose of GEN1160.
  • History of symptomatic disease (eg, rheumatoid arthritis, systemic progressive sclerosis [scleroderma], systemic lupus erythematosus, Sjögren's syndrome, autoimmune vasculitis [eg, Wegener's granulomatosis]).
  • Has cardiac disease, including:

    • Myocardial infarction within 6 months prior to the first dose of GEN1160, or unstable or uncontrolled disease/condition related to or affecting cardiac function (eg, unstable angina, congestive heart failure, Class III or IV), cardiac arrhythmia ( [CTCAE] Version 5.0 Grade 2 or higher), or clinically significant (ECG) abnormalities.
    • Screening 12-lead ECG showing a baseline as corrected by QTcF > 480 milliseconds (msec).
    • Echocardiogram (ECHO) or multigated acquisition () scan with left ventricular ejection fraction (LVEF) \< 45%.
  • Has clinically significant toxicities from previous anticancer therapies that have not resolved to baseline levels or to Grade 1 or lower. Note, participants with ≤ Grade 2 neuropathy or alopecia are an exception to this criterion and may qualify for the trial.
  • Active (GVHD) requiring immune suppression regardless of grade.

Note: Other protocol-defined Inclusion and Exclusion criteria may apply.

Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
42 participants (actual)

Study arms

  • Experimental
    GEN1160

    GEN1160 monotherapy in escalating doses in the dose escalation part and at the recommended phase 2 dose in the expansion parts.

    Biological: GEN1160

Interventions

  • BiologicalGEN1160

    IV infusion of GEN1160

    Also known as: PRO1160

06

What researchers measure

Primary outcomes

  1. Dose Escalation: Number of Participants With Treatment-Emergent Adverse Events (TEAEs)

    An adverse event (AE) was any untoward medical occurrence in a participant or clinical trial participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE was therefore any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. TEAEs were events that occurred during treatment or AEs that started before Cycle 1 Day 1 and worsened during the on-treatment period. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.

    Time frame: Up to approximately 2 years, 7 months

  2. Dose Escalation: Number of Participants With Dose Limiting Toxicities (DLTs)

    A DLT was defined as any of the following during the DLT evaluation period if considered not clearly and incontrovertibly due to underlying disease/extraneous causes by the investigator or the sponsor: death not clearly due to underlying disease or extraneous causes, ≥ Grade 3 non-hematologic toxicity (with exceptions per protocol), the abnormality met the definition of drug-induced liver injury (DILI), Grade 4 anemia or Grade 3 anemia lasting \> 7 days (transfusions permitted), Grade 4 neutropenia lasting \> 7 days, Grade 4 thrombocytopenia lasting \> 7 days, or ≥ Grade 3 thrombocytopenia with clinically significant bleeding, ≥ Grade 3 febrile neutropenia (absolute neutrophil count \[ANC\] \< 1000/microliters (µL) with a single oral temperature measurement of ≥ 38.3 centigrade (ºC) (101Fahrenheit \[ºF\]) or a temperature of ≥ 38ºC (100.4ºF) sustained over a 1-hour period), dose delay ≥ 14 days due to toxicity that is not clearly related to the underlying disease or extraneous causes.

    Time frame: 28 days

Secondary outcomes

  1. Dose Escalation: Objective Response Rate (ORR) As Assessed by Investigator Using Lugano Criteria for NHL Participants and Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 for RCC/NPC Participants

    ORR =percentage of participants with best overall response of complete response (CR) or partial response (PR). CR per Lugano:lymph nodes/extralymphatic sites score 1,2,3 with/without residual mass on 5- performance status, target nodes/nodal masses regress to ≤1.5cm in longest diameter, no extralymphatic disease sites/new lesions/non-measured lesion, organ enlargement regressed to normal, no evidence of specified disease in marrow/marrow normal by morphology. CR per RECIST=disappearance of all target lesions/pathological lymph nodes reduction short axis to\<10mm. PR per Lugano:lymph nodes/extralymphatic sites score 4/5 with reduced uptake vs baseline and residual mass of any size,≥50% decrease in sum of product diameters of up to 6 target nodes, no increase in non-measured lesion, spleen length regressed\>50% beyond normal, residual uptake higher than normal marrow but reduced vs baseline. PR per RECIST:≥ 30% decrease in sum of diameters of target lesions. Full details in protocol.

    Time frame: Up to approximately 2 years, 7 months

  2. Dose Escalation: Disease Control Rate (DCR)

    DCR was defined as the percentage of participants having stable disease (SD) or achieving a PR or CR (DCR = SD + PR + CR).

    Time frame: Up to approximately 2 years, 7 months

  3. Dose Escalation: Progression-free Survival (PFS)

    PFS was defined as the time from Cycle 1 Day 1 to first documented progressive disease or death due to any cause, whichever occurred earlier.

    Time frame: Up to approximately 2 years, 7 months

  4. Dose Escalation: Duration of Objective Response (DOR)

    DOR was defined as the time from the first documentation of response (CR or PR) to the date of progressive disease or death, whichever occurred earlier.

    Time frame: Up to approximately 2 years, 7 months

  5. Dose Escalation: Peak Plasma Concentration (Cmax) of GEN1160-related Analytes

    Serum samples were taken for analysis of GEN1160-related analytes. Related analytes were total antibody, AC-exatecan, and unconjugated-exatecan.

    Time frame: Cycle 1 and Cycle 3 (cycles were 21 days)

  6. Dose Escalation: Time to Maximum Concentration (Tmax) of GEN1160-related Analytes

    Serum samples were taken for analysis of GEN1160-related analytes. Related analytes were total antibody, AC-exatecan, and unconjugated-exatecan.

    Time frame: Cycle 1 and Cycle 3 (cycles were 21 days)

  7. Dose Escalation: Area Under the Curve up to the Last Quantifiable Time-point (AUC0-last) of GEN1160-related Analytes

    Serum samples were taken for analysis of GEN1160-related analytes. Related analytes were total antibody, AC-exatecan, and unconjugated-exatecan.

    Time frame: Cycle 1 and Cycle 3 (cycles were 21 days)

  8. Dose Escalation: Number of Participants With Antidrug Antibodies (ADA) to GEN1160

    Serum samples were taken for analysis of ADAs to GEN1160.

    Time frame: Up to approximately 2 years, 7 months

07

Results

Posted Nov 19, 2026
Limitations and caveats
This trial was terminated due to slow enrolment at the completion of Dose Escalation and did not proceed to Expansion Part A or B.

Participant flow

Participant flow — Overall Study
MilestoneDose Escalation: GEN1160 Dose Level 1 RCC/NPCDose Escalation: GEN1160 Dose Level 2 RCC/NPCDose Escalation: GEN1160 Dose Level 3 RCC/NPCDose Escalation: GEN1160 Dose Level 4 RCC/NPCDose Escalation: GEN1160 Dose Level 5 RCC/NPCDose Escalation: GEN1160 Dose Level 6 RCC/NPCDose Escalation: GEN1160 Dose Level 2 NHLDose Escalation: GEN1160 Dose Level 3 NHLDose Escalation: GEN1160 Dose Level 5 NHL
Started1511385351
Received at least 1 dose of treatment1511385351
Completed120022000
Not completed0311363351
Withdrew: Death035211030
Withdrew: Lost to follow-up000100000
Withdrew: Clinical disease progression000010000
Withdrew: Moved to alternative treatment by pi decision000000001
Withdrew: Physician decision000002000
Withdrew: Study terminated by sponsor001020210
Withdrew: Participant refused follow-up for survival000010000
Withdrew: Participant refused to participate in the follow-up survival period survey001000000
Withdrew: Withdrawal by subject004010110

Outcome measures

PrimaryDose Escalation: Number of Participants With Treatment-Emergent Adverse Events (TEAEs)

An adverse event (AE) was any untoward medical occurrence in a participant or clinical trial participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE was therefore any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. TEAEs were events that occurred during treatment or AEs that started before Cycle 1 Day 1 and worsened during the on-treatment period. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.

Time frame:
Up to approximately 2 years, 7 months
Reported as:
Count of participants · Participants
Dose Escalation: Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
ParticipantsDose Escalation: GEN1160 Dose Level 1 RCC/NPCDose Escalation: GEN1160 Dose Level 2 RCC/NPCDose Escalation: GEN1160 Dose Level 3 RCC/NPCDose Escalation: GEN1160 Dose Level 4 RCC/NPCDose Escalation: GEN1160 Dose Level 5 RCC/NPCDose Escalation: GEN1160 Dose Level 6 RCC/NPCDose Escalation: GEN1160 Dose Level 2 NHLDose Escalation: GEN1160 Dose Level 3 NHLDose Escalation: GEN1160 Dose Level 5 NHL
Dose Escalation: Number of Participants With Treatment-Emergent Adverse Events (TEAEs)1511385351
PrimaryDose Escalation: Number of Participants With Dose Limiting Toxicities (DLTs)

A DLT was defined as any of the following during the DLT evaluation period if considered not clearly and incontrovertibly due to underlying disease/extraneous causes by the investigator or the sponsor: death not clearly due to underlying disease or extraneous causes, ≥ Grade 3 non-hematologic toxicity (with exceptions per protocol), the abnormality met the definition of drug-induced liver injury (DILI), Grade 4 anemia or Grade 3 anemia lasting \> 7 days (transfusions permitted), Grade 4 neutropenia lasting \> 7 days, Grade 4 thrombocytopenia lasting \> 7 days, or ≥ Grade 3 thrombocytopenia with clinically significant bleeding, ≥ Grade 3 febrile neutropenia (absolute neutrophil count \[ANC\] \< 1000/microliters (µL) with a single oral temperature measurement of ≥ 38.3 centigrade (ºC) (101Fahrenheit \[ºF\]) or a temperature of ≥ 38ºC (100.4ºF) sustained over a 1-hour period), dose delay ≥ 14 days due to toxicity that is not clearly related to the underlying disease or extraneous causes.

Time frame:
28 days
Reported as:
Count of participants · Participants
Dose Escalation: Number of Participants With Dose Limiting Toxicities (DLTs)
ParticipantsDose Escalation: GEN1160 Dose Level 1 RCC/NPCDose Escalation: GEN1160 Dose Level 2 RCC/NPCDose Escalation: GEN1160 Dose Level 3 RCC/NPCDose Escalation: GEN1160 Dose Level 4 RCC/NPCDose Escalation: GEN1160 Dose Level 5 RCC/NPCDose Escalation: GEN1160 Dose Level 6 RCC/NPCDose Escalation: GEN1160 Dose Level 2 NHLDose Escalation: GEN1160 Dose Level 3 NHLDose Escalation: GEN1160 Dose Level 5 NHL
Dose Escalation: Number of Participants With Dose Limiting Toxicities (DLTs)002111000
SecondaryDose Escalation: Objective Response Rate (ORR) As Assessed by Investigator Using Lugano Criteria for NHL Participants and Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 for RCC/NPC Participants

ORR =percentage of participants with best overall response of complete response (CR) or partial response (PR). CR per Lugano:lymph nodes/extralymphatic sites score 1,2,3 with/without residual mass on 5- performance status, target nodes/nodal masses regress to ≤1.5cm in longest diameter, no extralymphatic disease sites/new lesions/non-measured lesion, organ enlargement regressed to normal, no evidence of specified disease in marrow/marrow normal by morphology. CR per RECIST=disappearance of all target lesions/pathological lymph nodes reduction short axis to\<10mm. PR per Lugano:lymph nodes/extralymphatic sites score 4/5 with reduced uptake vs baseline and residual mass of any size,≥50% decrease in sum of product diameters of up to 6 target nodes, no increase in non-measured lesion, spleen length regressed\>50% beyond normal, residual uptake higher than normal marrow but reduced vs baseline. PR per RECIST:≥ 30% decrease in sum of diameters of target lesions. Full details in protocol.

Time frame:
Up to approximately 2 years, 7 months
Reported as:
Number · percentage of participants
Dose Escalation: Objective Response Rate (ORR) As Assessed by Investigator Using Lugano Criteria for NHL Participants and Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 for RCC/NPC Participants
percentage of participantsDose Escalation: GEN1160 Dose Level 1 RCC/NPCDose Escalation: GEN1160 Dose Level 2 RCC/NPCDose Escalation: GEN1160 Dose Level 3 RCC/NPCDose Escalation: GEN1160 Dose Level 4 RCC/NPCDose Escalation: GEN1160 Dose Level 5 RCC/NPCDose Escalation: GEN1160 Dose Level 6 RCC/NPCDose Escalation: GEN1160 Dose Level 2 NHLDose Escalation: GEN1160 Dose Level 3 NHLDose Escalation: GEN1160 Dose Level 5 NHL
Dose Escalation: Objective Response Rate (ORR) As Assessed by Investigator Using Lugano Criteria for NHL Participants and Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 for RCC/NPC Participants0 (0.0 to 97.5)0 (0.0 to 52.2)9.1 (0.2 to 41.3)0 (0.0 to 84.2)12.5 (0.3 to 52.7)0 (0.0 to 52.2)33.3 (0.8 to 90.6)60.0 (14.7 to 94.7)100 (2.5 to 100.0)
SecondaryDose Escalation: Disease Control Rate (DCR)

DCR was defined as the percentage of participants having stable disease (SD) or achieving a PR or CR (DCR = SD + PR + CR).

Time frame:
Up to approximately 2 years, 7 months
Reported as:
Number · percentage of participants
Dose Escalation: Disease Control Rate (DCR)
percentage of participantsDose Escalation: GEN1160 Dose Level 1 RCC/NPCDose Escalation: GEN1160 Dose Level 2 RCC/NPCDose Escalation: GEN1160 Dose Level 3 RCC/NPCDose Escalation: GEN1160 Dose Level 4 RCC/NPCDose Escalation: GEN1160 Dose Level 5 RCC/NPCDose Escalation: GEN1160 Dose Level 6 RCC/NPCDose Escalation: GEN1160 Dose Level 2 NHLDose Escalation: GEN1160 Dose Level 3 NHLDose Escalation: GEN1160 Dose Level 5 NHL
Dose Escalation: Disease Control Rate (DCR)100 (2.5 to 100.0)80.0 (28.4 to 99.5)72.7 (39.0 to 94.0)50.0 (1.3 to 98.7)87.5 (47.3 to 99.7)60.0 (14.7 to 94.7)33.3 (0.8 to 90.6)80.0 (28.4 to 99.5)100 (2.5 to 100.0)
SecondaryDose Escalation: Progression-free Survival (PFS)

PFS was defined as the time from Cycle 1 Day 1 to first documented progressive disease or death due to any cause, whichever occurred earlier.

Time frame:
Up to approximately 2 years, 7 months
Reported as:
Median · months
Dose Escalation: Progression-free Survival (PFS)
monthsDose Escalation: GEN1160 Dose Level 1 RCC/NPCDose Escalation: GEN1160 Dose Level 2 RCC/NPCDose Escalation: GEN1160 Dose Level 3 RCC/NPCDose Escalation: GEN1160 Dose Level 4 RCC/NPCDose Escalation: GEN1160 Dose Level 5 RCC/NPCDose Escalation: GEN1160 Dose Level 6 RCC/NPCDose Escalation: GEN1160 Dose Level 2 NHLDose Escalation: GEN1160 Dose Level 3 NHLDose Escalation: GEN1160 Dose Level 5 NHL
Dose Escalation: Progression-free Survival (PFS)2.84.2 (1.8 to NA)5.4 (1.4 to NA)NA (1.2 to NA)4.8 (1.3 to NA)2.6 (1.1 to NA)1.3 (1.3 to NA)4.0 (1.3 to NA)NA (NA to NA)
SecondaryDose Escalation: Duration of Objective Response (DOR)

DOR was defined as the time from the first documentation of response (CR or PR) to the date of progressive disease or death, whichever occurred earlier.

Time frame:
Up to approximately 2 years, 7 months
Reported as:
Median · months
Dose Escalation: Duration of Objective Response (DOR)
monthsDose Escalation: GEN1160 Dose Level 1 RCC/NPCDose Escalation: GEN1160 Dose Level 2 RCC/NPCDose Escalation: GEN1160 Dose Level 3 RCC/NPCDose Escalation: GEN1160 Dose Level 4 RCC/NPCDose Escalation: GEN1160 Dose Level 5 RCC/NPCDose Escalation: GEN1160 Dose Level 6 RCC/NPCDose Escalation: GEN1160 Dose Level 2 NHLDose Escalation: GEN1160 Dose Level 3 NHLDose Escalation: GEN1160 Dose Level 5 NHL
Dose Escalation: Duration of Objective Response (DOR)——NA—11.0—9.21.5 (NA to NA)NA
SecondaryDose Escalation: Peak Plasma Concentration (Cmax) of GEN1160-related Analytes

Serum samples were taken for analysis of GEN1160-related analytes. Related analytes were total antibody, AC-exatecan, and unconjugated-exatecan.

Time frame:
Cycle 1 and Cycle 3 (cycles were 21 days)
Reported as:
Geometric mean · nanograms per milliliter (ng/ml)
Dose Escalation: Peak Plasma Concentration (Cmax) of GEN1160-related Analytes
nanograms per milliliter (ng/ml)Dose Escalation: GEN1160 Dose Level 1 RCC/NPCDose Escalation: GEN1160 Dose Level 2 RCC/NPCDose Escalation: GEN1160 Dose Level 3 RCC/NPCDose Escalation: GEN1160 Dose Level 4 RCC/NPCDose Escalation: GEN1160 Dose Level 5 RCC/NPCDose Escalation: GEN1160 Dose Level 6 RCC/NPCDose Escalation: GEN1160 Dose Level 2 NHLDose Escalation: GEN1160 Dose Level 3 NHLDose Escalation: GEN1160 Dose Level 5 NHL
Total Antibody Cycle 126912.4068798.86 ± 28.387114.23 ± 22.490507.21 ± 30.8139695.48 ± 16.4150329.90 ± 12.266595.65 ± 26.7100934.62 ± 24.077402.80
Total Antibody Cycle 340062.8086083.11 ± 31.987487.78 ± 27.8133915.00101628.03 ± 38.5138101.20 ± 44.458200.00104881.09 ± 47.997633.20
AC-exatecan Cycle 1609.01233.6 ± 9.31703.4 ± 23.81683.3 ± 23.62679.7 ± 16.33058.1 ± 29.21276.8 ± 12.11730.3 ± 24.11520.0
AC-exatecan Cycle 3704.01588.2 ± 26.11562.2 ± 25.31600.02351.5 ± 44.22781.7 ± 37.51230.01586.8 ± 19.01960.0
Unconjugated-exatecan Cycle 11.5003.821 ± 33.05.833 ± 46.19.479 ± 39.611.128 ± 92.511.074 ± 32.65.030 ± 18.35.399 ± 32.512.000
Unconjugated-exatecan Cycle 31.5504.151 ± 72.85.382 ± 47.38.0608.428 ± 43.910.900 ± 38.44.6702.638 ± 99.68.970
SecondaryDose Escalation: Time to Maximum Concentration (Tmax) of GEN1160-related Analytes

Serum samples were taken for analysis of GEN1160-related analytes. Related analytes were total antibody, AC-exatecan, and unconjugated-exatecan.

Time frame:
Cycle 1 and Cycle 3 (cycles were 21 days)
Reported as:
Median · days
Dose Escalation: Time to Maximum Concentration (Tmax) of GEN1160-related Analytes
daysDose Escalation: GEN1160 Dose Level 1 RCC/NPCDose Escalation: GEN1160 Dose Level 2 RCC/NPCDose Escalation: GEN1160 Dose Level 3 RCC/NPCDose Escalation: GEN1160 Dose Level 4 RCC/NPCDose Escalation: GEN1160 Dose Level 5 RCC/NPCDose Escalation: GEN1160 Dose Level 6 RCC/NPCDose Escalation: GEN1160 Dose Level 2 NHLDose Escalation: GEN1160 Dose Level 3 NHLDose Escalation: GEN1160 Dose Level 5 NHL
Total Antibody Cycle 10.033 (0.033 to 0.033)0.038 (0.03 to 0.11)0.037 (0.03 to 0.12)0.036 (0.03 to 0.09)0.057 (0.03 to 0.81)0.026 (0.02 to 0.04)0.092 (0.03 to 0.15)0.122 (0.03 to 0.14)0.035 (0.035 to 0.035)
Total Antibody Cycle 30.033 (0.033 to 0.033)0.064 (0.03 to 0.11)0.063 (0.03 to 0.90)0.044 (0.044 to 0.044)0.039 (0.03 to 0.09)0.069 (0.03 to 0.11)0.124 (0.124 to 0.124)0.118 (0.02 to 0.12)0.034 (0.034 to 0.034)
AC-exatecan Cycle 10.033 (0.033 to 0.033)0.038 (0.03 to 0.11)0.037 (0.03 to 0.12)0.036 (0.03 to 0.09)0.041 (0.03 to 0.11)0.033 (0.02 to 0.11)0.072 (0.03 to 0.09)0.065 (0.03 to 0.12)0.035 (0.035 to 0.035)
AC-exatecan Cycle 30.033 (0.033 to 0.033)0.034 (0.03 to 0.04)0.033 (0.03 to 0.11)0.044 (0.044 to 0.044)0.060 (0.03 to 0.13)0.034 (0.03 to 0.04)0.048 (0.048 to 0.048)0.034 (0.02 to 0.05)0.102 (0.102 to 0.102)
Unconjugated-exatecan Cycle 11.058 (1.058 to 1.058)1.018 (0.90 to 3.01)0.966 (0.79 to 1.11)1.050 (1.02 to 2.96)1.671 (0.81 to 6.90)2.103 (0.74 to 4.06)1.134 (1.00 to 2.83)0.885 (0.84 to 2.99)0.728 (0.728 to 0.728)
Unconjugated-exatecan Cycle 31.023 (1.023 to 1.023)1.538 (0.92 to 3.05)0.925 (0.74 to 2.76)0.958 (0.958 to 0.958)1.015 (0.99 to 2.00)1.942 (0.98 to 2.91)3.690 (3.690 to 3.690)0.832 (0.12 to 8.87)0.863 (0.863 to 0.863)
SecondaryDose Escalation: Area Under the Curve up to the Last Quantifiable Time-point (AUC0-last) of GEN1160-related Analytes

Serum samples were taken for analysis of GEN1160-related analytes. Related analytes were total antibody, AC-exatecan, and unconjugated-exatecan.

Time frame:
Cycle 1 and Cycle 3 (cycles were 21 days)
Reported as:
Geometric least squares mean · day*ng/mL
Dose Escalation: Area Under the Curve up to the Last Quantifiable Time-point (AUC0-last) of GEN1160-related Analytes
day*ng/mLDose Escalation: GEN1160 Dose Level 1 RCC/NPCDose Escalation: GEN1160 Dose Level 2 RCC/NPCDose Escalation: GEN1160 Dose Level 3 RCC/NPCDose Escalation: GEN1160 Dose Level 4 RCC/NPCDose Escalation: GEN1160 Dose Level 5 RCC/NPCDose Escalation: GEN1160 Dose Level 6 RCC/NPCDose Escalation: GEN1160 Dose Level 2 NHLDose Escalation: GEN1160 Dose Level 3 NHLDose Escalation: GEN1160 Dose Level 5 NHL
Total Antibody Cycle 176755.338232276.559 ± 17.7334061.153 ± 33.0269213.463 ± 21.3550056.322 ± 27.7698705.608 ± 23.2271275.855 ± 26.0456216.535 ± 23.5351585.995
Total Antibody Cycle 3102735.629362233.965 ± 32.5352217.495 ± 42.9193252.651481017.681 ± 38.7680713.940 ± 45.3427201.677586698.427 ± 58.2509667.449
AC-exatecan Cycle 11506.7583604.888 ± 22.45272.914 ± 27.64608.437 ± 5.69105.011 ± 32.912920.183 ± 21.34451.604 ± 0.96174.833 ± 7.45977.469
AC-exatecan Cycle 31797.6995106.784 ± 32.84988.139 ± 40.73530.8937995.783 ± 33.512829.939 ± 47.55350.2587433.467 ± 37.07756.499
Unconjugated-exatecan Cycle 18.08823.281 ± 35.434.721 ± 44.545.652 ± 45.974.917 ± 43.895.424 ± 37.336.611 ± 45.631.710 ± 22.847.218
Unconjugated-exatecan Cycle 38.48525.096 ± 65.031.692 ± 32.828.45349.378 ± 33.199.175 ± 37.733.81424.595 ± 89.939.469
SecondaryDose Escalation: Number of Participants With Antidrug Antibodies (ADA) to GEN1160

Serum samples were taken for analysis of ADAs to GEN1160.

Time frame:
Up to approximately 2 years, 7 months
Reported as:
Count of participants · Participants
Dose Escalation: Number of Participants With Antidrug Antibodies (ADA) to GEN1160
ParticipantsDose Escalation: GEN1160 Dose Level 1 RCC/NPCDose Escalation: GEN1160 Dose Level 2 RCC/NPCDose Escalation: GEN1160 Dose Level 3 RCC/NPCDose Escalation: GEN1160 Dose Level 4 RCC/NPCDose Escalation: GEN1160 Dose Level 5 RCC/NPCDose Escalation: GEN1160 Dose Level 6 RCC/NPCDose Escalation: GEN1160 Dose Level 2 NHLDose Escalation: GEN1160 Dose Level 3 NHLDose Escalation: GEN1160 Dose Level 5 NHL
Dose Escalation: Number of Participants With Antidrug Antibodies (ADA) to GEN1160012000000

Adverse events

Collected over Up to approximately 2 years, 7 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Dose Escalation: GEN1160 Dose Level 1 RCC/NPC0/1 (0%)0/1 (0%)1/1 (100%)
Dose Escalation: GEN1160 Dose Level 2 RCC/NPC3/5 (60%)2/5 (40%)5/5 (100%)
Dose Escalation: GEN1160 Dose Level 3 RCC/NPC6/11 (54.5%)5/11 (45.5%)11/11 (100%)
Dose Escalation: GEN1160 Dose Level 4 RCC/NPC2/3 (66.7%)1/3 (33.3%)3/3 (100%)
Dose Escalation: GEN1160 Dose Level 5 RCC/NPC1/8 (12.5%)4/8 (50%)8/8 (100%)
Dose Escalation: GEN1160 Dose Level 6 RCC/NPC1/5 (20%)5/5 (100%)4/5 (80%)
Dose Escalation: GEN1160 Dose Level 2 NHL0/3 (0%)0/3 (0%)3/3 (100%)
Dose Escalation: GEN1160 Dose Level 3 NHL3/5 (60%)0/5 (0%)5/5 (100%)
Dose Escalation: GEN1160 Dose Level 5 NHL0/1 (0%)0/1 (0%)1/1 (100%)
Most frequent serious events
Showing 10 of 29
Most frequent serious events
EventDose Escalation: GEN1160 Dose Level 1 RCC/NPCDose Escalation: GEN1160 Dose Level 2 RCC/NPCDose Escalation: GEN1160 Dose Level 3 RCC/NPCDose Escalation: GEN1160 Dose Level 4 RCC/NPCDose Escalation: GEN1160 Dose Level 5 RCC/NPCDose Escalation: GEN1160 Dose Level 6 RCC/NPCDose Escalation: GEN1160 Dose Level 2 NHLDose Escalation: GEN1160 Dose Level 3 NHLDose Escalation: GEN1160 Dose Level 5 NHL
NeutropeniaBlood and lymphatic system disorders0/10/51/110/30/83/50/30/50/1
ThrombocytopeniaBlood and lymphatic system disorders0/10/51/110/30/82/50/30/50/1
HyponatraemiaMetabolism and nutrition disorders0/10/50/111/30/80/50/30/50/1
Febrile neutropeniaBlood and lymphatic system disorders0/10/50/110/32/80/50/30/50/1
DyspnoeaRespiratory, thoracic and mediastinal disorders0/10/50/110/30/81/50/30/50/1
DiarrhoeaGastrointestinal disorders0/10/50/110/30/81/50/30/50/1
Humerus fractureInjury, poisoning and procedural complications0/10/50/110/30/81/50/30/50/1
FatigueGeneral disorders0/10/51/110/30/81/50/30/50/1
Muscular weaknessMusculoskeletal and connective tissue disorders0/10/50/110/30/81/50/30/50/1
Pleural effusionRespiratory, thoracic and mediastinal disorders0/10/50/110/30/81/50/30/50/1
Most frequent other events
Showing 10 of 106
Most frequent other events
EventDose Escalation: GEN1160 Dose Level 1 RCC/NPCDose Escalation: GEN1160 Dose Level 2 RCC/NPCDose Escalation: GEN1160 Dose Level 3 RCC/NPCDose Escalation: GEN1160 Dose Level 4 RCC/NPCDose Escalation: GEN1160 Dose Level 5 RCC/NPCDose Escalation: GEN1160 Dose Level 6 RCC/NPCDose Escalation: GEN1160 Dose Level 2 NHLDose Escalation: GEN1160 Dose Level 3 NHLDose Escalation: GEN1160 Dose Level 5 NHL
Gastrooesophageal reflux diseaseGastrointestinal disorders0/11/50/110/30/80/50/30/51/1
DiarrhoeaGastrointestinal disorders0/11/53/111/33/81/50/33/51/1
Lymphocyte count increasedInvestigations0/10/50/110/30/80/50/30/51/1
ProteinuriaRenal and urinary disorders0/11/53/110/30/80/50/30/51/1
White blood cell count decreasedInvestigations0/12/53/111/31/80/51/34/51/1
NeutropeniaBlood and lymphatic system disorders0/12/52/110/34/82/51/35/51/1
HyponatraemiaMetabolism and nutrition disorders1/12/53/111/30/82/51/30/51/1
NauseaGastrointestinal disorders0/13/59/111/37/83/51/31/51/1
AnaemiaBlood and lymphatic system disorders0/13/55/112/33/82/52/33/51/1
ThrombocytopeniaBlood and lymphatic system disorders0/11/52/110/34/81/51/34/51/1

Baseline characteristics

Full Analysis Set (FAS) included all participants who received any amount of GEN1160. Participants were analyzed according to actual treatment (dose level).

Age, Categorical
Age, Categorical(Participants)Dose Escalation: GEN1160 Dose Level 1 RCC/NPCDose Escalation: GEN1160 Dose Level 2 RCC/NPCDose Escalation: GEN1160 Dose Level 3 RCC/NPCDose Escalation: GEN1160 Dose Level 4 RCC/NPCDose Escalation: GEN1160 Dose Level 5 RCC/NPCDose Escalation: GEN1160 Dose Level 6 RCC/NPCDose Escalation: GEN1160 Dose Level 2 NHLDose Escalation: GEN1160 Dose Level 3 NHLDose Escalation: GEN1160 Dose Level 5 NHLTotal
<=18 years0000000000
Between 18 and 65 years14917315132
>=65 years01221220010
Age, Continuous
Age, Continuous(years)Dose Escalation: GEN1160 Dose Level 1 RCC/NPCDose Escalation: GEN1160 Dose Level 2 RCC/NPCDose Escalation: GEN1160 Dose Level 3 RCC/NPCDose Escalation: GEN1160 Dose Level 4 RCC/NPCDose Escalation: GEN1160 Dose Level 5 RCC/NPCDose Escalation: GEN1160 Dose Level 6 RCC/NPCDose Escalation: GEN1160 Dose Level 2 NHLDose Escalation: GEN1160 Dose Level 3 NHLDose Escalation: GEN1160 Dose Level 5 NHLTotal
Mean6451 ± 16.253.4 ± 11.370.3 ± 11.256.6 ± 1159.8 ± 17.366 ± 2.654 ± 6.75557 ± 12.2
Sex: Female, Male
Sex: Female, Male(Participants)Dose Escalation: GEN1160 Dose Level 1 RCC/NPCDose Escalation: GEN1160 Dose Level 2 RCC/NPCDose Escalation: GEN1160 Dose Level 3 RCC/NPCDose Escalation: GEN1160 Dose Level 4 RCC/NPCDose Escalation: GEN1160 Dose Level 5 RCC/NPCDose Escalation: GEN1160 Dose Level 6 RCC/NPCDose Escalation: GEN1160 Dose Level 2 NHLDose Escalation: GEN1160 Dose Level 3 NHLDose Escalation: GEN1160 Dose Level 5 NHLTotal
Female0031101208
Male15827523134
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Dose Escalation: GEN1160 Dose Level 1 RCC/NPCDose Escalation: GEN1160 Dose Level 2 RCC/NPCDose Escalation: GEN1160 Dose Level 3 RCC/NPCDose Escalation: GEN1160 Dose Level 4 RCC/NPCDose Escalation: GEN1160 Dose Level 5 RCC/NPCDose Escalation: GEN1160 Dose Level 6 RCC/NPCDose Escalation: GEN1160 Dose Level 2 NHLDose Escalation: GEN1160 Dose Level 3 NHLDose Escalation: GEN1160 Dose Level 5 NHLTotal
Hispanic or Latino0010010114
Not Hispanic or Latino151038434038
Unknown0000000000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Dose Escalation: GEN1160 Dose Level 1 RCC/NPCDose Escalation: GEN1160 Dose Level 2 RCC/NPCDose Escalation: GEN1160 Dose Level 3 RCC/NPCDose Escalation: GEN1160 Dose Level 4 RCC/NPCDose Escalation: GEN1160 Dose Level 5 RCC/NPCDose Escalation: GEN1160 Dose Level 6 RCC/NPCDose Escalation: GEN1160 Dose Level 2 NHLDose Escalation: GEN1160 Dose Level 3 NHLDose Escalation: GEN1160 Dose Level 5 NHLTotal
American Indian or Alaska Native0000000000
Asian02412114015
Black or African American0010120004
Native Hawaiian or Other Pacific Islander0000000000
Not Reported0000000000
Other0000001012
Unknown0000000000
White13625211021
Region of Enrollment
Region of Enrollment(Participants)Dose Escalation: GEN1160 Dose Level 1 RCC/NPCDose Escalation: GEN1160 Dose Level 2 RCC/NPCDose Escalation: GEN1160 Dose Level 3 RCC/NPCDose Escalation: GEN1160 Dose Level 4 RCC/NPCDose Escalation: GEN1160 Dose Level 5 RCC/NPCDose Escalation: GEN1160 Dose Level 6 RCC/NPCDose Escalation: GEN1160 Dose Level 2 NHLDose Escalation: GEN1160 Dose Level 3 NHLDose Escalation: GEN1160 Dose Level 5 NHLTotal
China02411013012
United States13727522130
08

Study locations

17 sites
  • City of Hope Comprehensive Cancer Center - Duarte
    Duarte, California 91010, United States
  • The City of Hope Orange County Lennar Foundation Cancer Center
    Irvine, California 92618, United States
  • University of Michigan
    Ann Arbor, Michigan 48109, United States
  • Karmanos Cancer Institute
    Detroit, Michigan 48201, United States
  • Washington University School of Medicine in St. Louis
    St Louis, Missouri 63110, United States
  • NYU Langone Health
    New York, New York 10016, United States
  • Montefiore Medical Center - Montefiore Hospital
    The Bronx, New York 10467, United States
  • Levine Cancer Center
    Charlotte, North Carolina 28204, United States
  • Cleveland Clinic - Euclid Hospital
    Cleveland, Ohio 44195, United States
  • Providence Portland Medical Center
    Portland, Oregon 97213, United States
  • Oregon Health & Science University
    Portland, Oregon 97239, United States
  • Sarah Cannon Research Institute - Nashville
    Nashville, Tennessee 37203, United States
  • MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • START Mountain Cancer Center
    West Valley City, Utah 84119, United States
  • Cancer Hospital of Chinese Academy of Medical Sciences
    Beijing, Beijing Municipality, China
  • Fudan University Shanghai Cancer Center
    Shanghai, Shanghai Municipality, China
  • Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
    Shanghai, Shanghai Municipality, China
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2023 to primary completion in Nov 2025, 31 months.

Results were first posted in Nov 2026, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 31, 2023
First posted
Feb 9, 2023
StartActual
Mar 15, 2023
Primary completionActual
Nov 5, 2025
CompletionActual
Nov 5, 2025
Results first posted
Nov 19, 2026
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Nov 19, 2026
Primary outcomes
2 edited, 1 removed
What changed in the outcomes
  • EditedDose Escalation: Number of Participants withWith Treatment-Emergent Adverse Events (TEAEs)Time frame: Up to approximately 1 year → Up to approximately 2 years, 7 months
  • EditedDose Escalation: Number of Participants withWith Dose Limiting Toxicities (DLTs)Time frame: 28 days
  • RemovedExpansion Parts A and B: Objective Response Rate (ORR)Time frame: Up to approximately 1 year
Nov 19, 2026
Documents
Secondary outcomes
6 edited, 1 time frame changed, 1 added, 6 removed, 1 description edited
What changed in the outcomes
  • EditedDose Escalation and Expansion Parts A and B: Progression-free Survival (PFS)Time frame: Up to approximately 18 months → Up to approximately 2 years, 7 months
  • EditedDose Escalation and Expansion Parts A and B: Duration of Objective Response (DOR)Time frame: Up to approximately 1 year → Up to approximately 2 years, 7 months
  • EditedDose Escalation and Expansion Parts A and B: Peak Plasma Concentration (Cmax) of GEN1160-related AnalytesTime frame: Up to approximately 1 year → Cycle 1 and Cycle 3 (cycles were 21 days)
  • EditedDose Escalation and Expansion Parts A and B: Time to Maximum Concentration (Tmax) of GEN1160-related AnalytesTime frame: Up to approximately 1 year → Cycle 1 and Cycle 3 (cycles were 21 days)
  • EditedDose Escalation and Expansion Parts A and B: Area Under the Curve up to the Last Quantifiable Time-point (AUC0-last) of GEN1160-related AnalytesTime frame: Up to approximately 1 year → Cycle 1 and Cycle 3 (cycles were 21 days)
  • EditedDose Escalation and Expansion Parts A and B: Number of Participants withWith Antidrug Antibodies (ADA) to GEN1160Time frame: Up to approximately 1 year → Up to approximately 2 years, 7 months
  • AddedDose Escalation: Objective Response Rate (ORR) As Assessed by Investigator Using Lugano Criteria for NHL Participants and Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 for RCC/NPC ParticipantsTime frame: Up to approximately 2 years, 7 months
  • RemovedDose Escalation: ORRTime frame: Up to approximately 1 year
  • RemovedExpansion Parts A and B: Complete Response (CR) RateTime frame: Up to approximately 1 year
  • RemovedExpansion Parts A and B: Overall Survival (OS)Time frame: Up to approximately 18 months
  • RemovedExpansion Parts A and B: Number of Participants with TEAEsTime frame: Up to approximately 1 year
  • RemovedExpansion Parts A and B: Number of Participants with Anti-GEN1160 AntibodiesTime frame: Up to approximately 1 year
  • RemovedExpansion Parts A and B: Time-to response (TTR)Time frame: Up to approximately 1 year
  • Time frameDose Escalation: Disease Control Rate (DCR)Up to approximately 1 year → Up to approximately 2 years, 7 months
  • DescriptionDose Escalation: Disease Control Rate (DCR): how it is measured was reworded
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    Results posted
    Primary outcomes 2 edited, 1 removed
    What changed in the outcomes
    • EditedDose Escalation: Number of Participants withWith Treatment-Emergent Adverse Events (TEAEs)Time frame: Up to approximately 1 year → Up to approximately 2 years, 7 months
    • EditedDose Escalation: Number of Participants withWith Dose Limiting Toxicities (DLTs)Time frame: 28 days
    • RemovedExpansion Parts A and B: Objective Response Rate (ORR)Time frame: Up to approximately 1 year
    Secondary outcomes 6 edited, 1 time frame changed, 1 added, 6 removed, 1 description edited
    What changed in the outcomes
    • EditedDose Escalation and Expansion Parts A and B: Progression-free Survival (PFS)Time frame: Up to approximately 18 months → Up to approximately 2 years, 7 months
    • EditedDose Escalation and Expansion Parts A and B: Duration of Objective Response (DOR)Time frame: Up to approximately 1 year → Up to approximately 2 years, 7 months
    • EditedDose Escalation and Expansion Parts A and B: Peak Plasma Concentration (Cmax) of GEN1160-related AnalytesTime frame: Up to approximately 1 year → Cycle 1 and Cycle 3 (cycles were 21 days)
    • EditedDose Escalation and Expansion Parts A and B: Time to Maximum Concentration (Tmax) of GEN1160-related AnalytesTime frame: Up to approximately 1 year → Cycle 1 and Cycle 3 (cycles were 21 days)
    • EditedDose Escalation and Expansion Parts A and B: Area Under the Curve up to the Last Quantifiable Time-point (AUC0-last) of GEN1160-related AnalytesTime frame: Up to approximately 1 year → Cycle 1 and Cycle 3 (cycles were 21 days)
    • EditedDose Escalation and Expansion Parts A and B: Number of Participants withWith Antidrug Antibodies (ADA) to GEN1160Time frame: Up to approximately 1 year → Up to approximately 2 years, 7 months
    • AddedDose Escalation: Objective Response Rate (ORR) As Assessed by Investigator Using Lugano Criteria for NHL Participants and Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 for RCC/NPC ParticipantsTime frame: Up to approximately 2 years, 7 months
    • RemovedDose Escalation: ORRTime frame: Up to approximately 1 year
    • RemovedExpansion Parts A and B: Complete Response (CR) RateTime frame: Up to approximately 1 year
    • RemovedExpansion Parts A and B: Overall Survival (OS)Time frame: Up to approximately 18 months
    • RemovedExpansion Parts A and B: Number of Participants with TEAEsTime frame: Up to approximately 1 year
    • RemovedExpansion Parts A and B: Number of Participants with Anti-GEN1160 AntibodiesTime frame: Up to approximately 1 year
    • RemovedExpansion Parts A and B: Time-to response (TTR)Time frame: Up to approximately 1 year
    • Time frameDose Escalation: Disease Control Rate (DCR)Up to approximately 1 year → Up to approximately 2 years, 7 months
    • DescriptionDose Escalation: Disease Control Rate (DCR): how it is measured was reworded
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05721222
Lead sponsor
Genmab
Responsible party
Sponsor
First posted
Feb 9, 2023
Start date
Mar 15, 2023
Primary completion
Nov 5, 2025
Completion
Nov 5, 2025
Results posted
Nov 19, 2026
Last update
Nov 19, 2026

Study contacts

Study Official
study director · Genmab

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion